Frank Palantoni joins Laboratoire M2 as CEO

SHERBROOKE, Québec, June 22, 2016 (GLOBE NEWSWIRE) -- Laboratoire M2, (LabM2) the company behind THYMOX™, the new standard in environmentally sustainable disinfecting technologies, is proud to announce that Frank Palantoni, a seasoned global executive, has joined the company as CEO.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/e33a443f-0747-4eab-965b-6b3d59333979

“I’m excited to work with Serge Auray, President and Founder, and the entire LabM2 team, at this important growth stage as our company transitions from a research and development platform, to executing a strategy of rapid commercial development of THYMOX™’s breakthrough technology in North America, Europe and Asia,” said Palantoni, who will be based in San Francisco.

THYMOX™’s disruptive and environmentally friendly antimicrobial technology is botanically derived to harnesses the power of nature’s own antimicrobial properties to tackle some of nature’s most difficult pathogenic problems.  Commercial use of THYMOX™ in agriculture and animal health has already saved the environment from poisoning by tons of heavy metals that would otherwise have been washed into the soil. The continued commercial expansion of THYMOX™ has the potential to eliminate the use of millions of pounds of copper sulfate in the dairy industry each year. In other sectors, including institutional and home environments, THYMOX™ products have eliminated chemicals which are otherwise environmentally damaging, and hazardous to humans.

Prior to being named CEO, Mr. Palantoni joined LabM2 as a strategic advisor in June 2015. Previously, Mr. Palantoni was President of Pet and Life Science Divisions at Central Garden & Pet (NASDAQ: CENTA) a leading animal health products company. During his 30 year career, Mr. Palantoni has served as Global CEO of Gerber Products, and CEO of Novartis Consumer Health, NA. Earlier, he was amongst the top executives at Groupe Danone, and held senior positions at Kraft and Procter & Gamble.

Mr. Palantoni is currently also a Director of Lexicon Pharmaceuticals (NASDAQ: LXRX), a biopharmaceutical company engaged in discovering and developing breakthrough treatments for human diseases such as cancer and diabetes. He holds a B.S. from Tufts University, and an MBA from Columbia University.

“We are pleased to have Frank Palantoni as the new CEO of LabM2 as we continue to grow. He has already had a great impact within our team since his arrival last June. His leadership and experience will continue to be very positive for the company, especially with the exciting opportunities we face,” says Mario Allaire, Chairman of the Board of Directors of LabM2.

International Expansion Accelerates

One of Mr. Palantoni’s main objectives will be the continued international commercial expansion of THYMOX™.  Fuelled by a round of investment, led by Canada’s leading cooperative financial group, Desjardins Innovatech ($200 billion in assets), which closed in 3rd quarter of 2015, LabM2 made significant commercial inroads into the Chinese and European animal health markets in the 1st quarter of 2016. Cycle Capital Management, the most active Canadian cleantech venture capital platform, which made its first LabM2 investment in 2012, also participated in last year’s round. In the second half of 2016, LabM2 will be focussing more of its attention on the North American animal health market, as well as boosting its efforts in crop and consumer sectors.

About Laboratoire M2

Laboratoire M2, based in Sherbrooke, Canada, has built a well-respected reputation for product innovation and expertise in environmentally sustainable “green” disinfection and bio-security technology under the trademark THYMOX™. The company currently markets a range of leading biodegradable, disinfecting and anti-microbial products based on their proprietary technology platform, which are environmentally certified by UL (Ecologo2794). In addition, Laboratoire M2 biodegradable animal health products are effective against the bacteria and fungus known to be the cause of damaging and costly bovine hoof infections (digital dermatitis) in the dairy industry. The company also distributes products and ingredients under private label agreements in institutional and retail markets, as well as in the crop protection market. For more information about Laboratoire M2 visit thymox.com

Contact: Mathieu  Lavallée (Canada)
[email protected] /514-947-7628
Contact: Marcia Clark (U.S.)
[email protected]/914-523-9314

You May Also Be Interested In

• Huize Holding Limited Files 2023 Annual Report on Form 20-F
• GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
• DEEPX Expands First-Generation AI Chips into Intelligent Security and Video Analytics Markets